Amgen Inc.

Vigil Neuroscience, Inc.

Vertex Pharmaceuticals, Inc.

Haoxuan Wang

Jonathan B Houze

Ryan D White

Gwenaella Rescourio

Vincent Santora

Yongwei Wu

Alice R Wong

Timothy Hopper

Lara C Czabaniuk

Jane Panteleev

Maxence Bos

John Mancuso

Ivan Franzoni

Michael Aaron Brodney

Jingrong Cao

Jon H Come

John E Cochran

Suganthini S Nanthakumar

Leslie A Dakin

Timothy J Senter

Brad D Maxwell

Steven David Stone

Elena Dolgikh

Samantha Angle

Jun Myun Ahn

Jessica Howard Olsen

Akira Joseph Shimizu

Isaac E Marx

Hardwin O'Dowd

Benjamin Charles Milgram

Alan H Cherney

Hardwin O′dowd

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

Inhibitors of APOL1 and methods of using same

The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (1).

The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.

Cyclobutyl dihydroquinoline sulfonamide compounds

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2').  This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Growing community of inventors

Thousand Oaks, CA, United States of America

Haoxuan Wang